Beskrywing

The MG (myasthenia gravis) drug market in China in terms of revenue is set to grow by US$ 565 miljoen tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 51% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for MG (myasthenia gravis) drug. The China MG (myasthenia gravis) drug market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as HBM Holdings Limited, Rongchang Pharmacy Co. Bpk..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the MG (myasthenia gravis) drug market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Streek: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China MG (myasthenia gravis) drug market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the MG (myasthenia gravis) drug market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. MG (Myasthenia Gravis) Drug Market by Region
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. Maatskappy profiele
5.1 HBM Holdings Limited
5.2 Rongchang Pharmacy Co., Bpk.
6. Bylaag
6.1 Oor StrategyHelix
6.2 Vrywaring